Nuvation Bio Secures Thermo Fisher for U.S. Manufacturing of Revenue-Generating Cancer Drug Ibtrozi
NUVB has more than doubled off its 52-week low of $1.57.
Summary
Nuvation Bio announced a collaboration with Thermo Fisher Scientific for the U.S.-based manufacturing of its drug, Ibtrozi, which treats ROS1-positive non-small cell lung cancer. This partnership follows Nuvation Bio's recent Q1 2026 earnings report, which highlighted $18.5 million in net product revenues specifically from Ibtrozi. Securing a manufacturing agreement with a major player like Thermo Fisher is a significant operational development, as it de-risks the supply chain for a key commercialized product. This move ensures consistent availability and supports future sales growth, strengthening Nuvation Bio's commercialization efforts for Ibtrozi. Investors will monitor the execution of this manufacturing partnership and its impact on Ibtrozi's sales trajectory.
At the time of this announcement, NUVB was trading at $4.78 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $1.57 to $9.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.